GLP-1 forever? What the evidence says about long-term use

What did @longevitypodcast actually say?

Honestly, not much that's medically evaluable. The transcript is largely incoherent, referencing games, a guitar, and "training" in ways that don't map to any identifiable GLP-1 claim. The caption asks "GLP1 für immer?" (GLP-1 forever?) and promises viewers will learn something "ganz wichtig" (very important), but the spoken content doesn't deliver a clear medical position.

This matters because the framing, the hashtags "fettwegspritze" (fat-away injection), "abnehmen" (weight loss), and "longevity," sets an expectation of medical guidance. When viewers arrive expecting GLP-1 advice and receive scattered commentary, the risk is that they fill in the gaps with their own assumptions, which can be more dangerous than a clearly wrong claim.

We cannot quote specific medical claims from this creator because the transcript doesn't contain them. What we can do is address the implied question: should people take GLP-1 medications indefinitely?

Does the science back up long-term GLP-1 use?

For the right patients, yes, and this is increasingly well-supported. The evidence for continuous use is actually stronger than most people realize, but it comes with important nuance that a 12-second caption cannot convey.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. A follow-up analysis published in Diabetes, Obesity and Metabolism confirmed this rebound effect. This strongly suggests obesity functions as a chronic condition requiring ongoing treatment, not a short course like an antibiotic.

The SELECT trial (Lincoff et al., 2023, NEJM) added cardiovascular outcome data, showing that semaglutide reduced major adverse cardiovascular events by 20% in overweight adults without diabetes over a median 34-month follow-up. That's a meaningful long-term benefit, not just a weight number on a scale.

Tirzepatide data from the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar rebound patterns after discontinuation, reinforcing the "forever or at least long-term" argument for eligible patients.

What did they get wrong, or right?

Because the transcript is essentially uninterpretable as medical content, we can't fairly say the creator got specific facts wrong. What we can flag is what the framing gets wrong by omission.

Asking "GLP-1 forever?" without addressing who "forever" is appropriate for is a real gap. These medications are not appropriate for everyone indefinitely. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 face contraindications. Patients who experience persistent gastrointestinal side effects, pancreatitis, or who are planning pregnancy need individualized reassessment.

The hashtag "fettwegspritze" is also worth calling out. It's a colloquial term that frames GLP-1 agonists as cosmetic fat-removal tools rather than medications for a chronic metabolic condition. That framing is not just inaccurate, it contributes to access problems by reinforcing the idea that these drugs are lifestyle shortcuts rather than evidence-based treatments.

Credit where it's due: raising the question of long-term use at all is worthwhile. Too many patients stop these medications after hitting a weight target, not understanding the relapse data.

What should you actually know?

The weight regain after stopping GLP-1 medications is not a personal failure. It reflects the underlying biology of how these drugs work. GLP-1 receptor agonists reduce appetite and slow gastric emptying partly by acting on brain circuits that regulate hunger. When you stop the drug, those circuits revert. The body is not broken; the drug was doing a job that the body cannot maintain independently in many people with obesity.

Long-term use decisions should be made with a prescribing clinician who knows your full picture, including cardiometabolic risk, side effect history, cost, and whether weight loss goals have been reached and are stable. There is no universal answer to "forever."

Cost and access remain serious real-world barriers. In Germany, where this content appears aimed, GLP-1 medications for obesity (not diabetes) are generally not covered by statutory health insurance as of 2024. Ongoing use means ongoing out-of-pocket expense for most patients, which is a clinical reality that social media content almost never addresses.

Anyone making a decision about long-term GLP-1 therapy based on a TikTok caption is working with about 1% of the information they actually need.